Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Deeper Understanding Emerging of KRAS Biology in NSCLC

Danielle Bucco
Published: Friday, Dec 15, 2017

Ferdinandos Skoulidis, MD, PhD

Ferdinandos Skoulidis, MD, PhD
Approximately 25% to 30% of patients with non–small cell lung cancer (NSCLC) have activating mutations in KRAS, creating a challenging unmet treatment need, explained Ferdinandos Skoulidis, MD, PhD.

-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.

OncLive: Please provide an overview of your presentation.

Skoulidis: I discussed the role of biomarkers in the management of NSCLC. This is a very topical theme because lung adenocarcinoma is emerging as the pinnacle of precision cancer medicine among the solid tumors, with the recognition that NSCLC does not constitute a single disease. NSCLC consists of many different molecularly definitive entities, each of which needs to be treated in a unique way.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication